Drug-Patent Cliffs
Invest in

Drug-Patent Cliffs

10.0%
7.8%
1.1%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
10.0%
7.8%
1.1%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
66.7% Generic Drugs 12.0%
18.7% Perrigo Company plc PRGO 6.8%
15.8% Mylan NV MYL --
8.7% Taro Pharmaceutical Industries Ltd. TARO 18.1%
7.5% Dr. Reddys Laboratories Ltd. ADS RDY 10.4%
3.7% Endo International PLC ENDP 31.6%
3.0% Mallinckrodt plc MNK 37.1%
2.4% Akorn Inc. AKRX 45.1%
2.0% Impax Laboratories Inc. IPXL 10.7%
1.7% Sagent Pharmaceuticals Inc. SGNT 44.9%
1.1% Teligent Inc (New) TLGT --
0.9% Amphastar Pharmaceuticals Inc (DE) AMPH 14.6%
0.8% Cambrex Corp. CBM 44.9%
0.6% Lannett Co. Inc. LCI 49.2%
31.5% Big Pharma 1.7%
24.5% Teva Pharmaceutical Industries Ltd ADR TEVA 6.5%
7.0% Abbott Laboratories ABT 14.9%
1.7% Biosimilars 1.1%
0.7% Momenta Pharmaceuticals Inc. MNTA 13.7%
0.5% Coherus BioSciences Inc CHRS 45.7%
0.5% Pfenex Inc PFNX 31.6%

Quotes delayed 15 mins. Currently Feb 7, 2016 4:24:24 PM. Fields are marked with -- when data is unavailable.